These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 35451995)

  • 21. P2Y12 Inhibitor Monotherapy vs Dual Antiplatelet Therapy After Deployment of a Drug-Eluting Stent: The SHARE Randomized Clinical Trial.
    Min PK; Kang TS; Cho YH; Cheong SS; Kim BK; Kwon SW; Park WJ; Lee JH; Kim W; Lee WS; Yoon YW; Lee BK; Kwon HM; Hong BK;
    JAMA Netw Open; 2024 Mar; 7(3):e240877. PubMed ID: 38451525
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical outcomes with 6 months dual antiplatelet therapy after implantation of biolimus-A9 drug eluting coronary stents.
    Cockburn J; Pareek N; Poliacikova P; Saraf S; Williams R; Dhillon G; Robinson D; Gerber R; Hatrick R; Blows L; de Belder A; Hildick-Smith D
    Int J Cardiol; 2014 Mar; 172(1):185-9. PubMed ID: 24462139
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Angiographic and clinical performance of polymer-free biolimus-eluting stent in patients with ST-segment elevation acute myocardial infarction in a metropolitan public hospital: The BESAMI MUCHO study.
    Sgueglia GA; D'Errico F; Gioffrè G; De Santis A; Summaria F; Piccioni F; Gaspardone A
    Catheter Cardiovasc Interv; 2018 Apr; 91(5):851-858. PubMed ID: 28766881
    [TBL] [Abstract][Full Text] [Related]  

  • 24. First-in-human evaluation of a bioabsorbable polymer-coated sirolimus-eluting stent: imaging and clinical results of the DESSOLVE I Trial (DES with sirolimus and a bioabsorbable polymer for the treatment of patients with de novo lesion in the native coronary arteries).
    Ormiston J; Webster M; Stewart J; Vrolix M; Whitbourn R; Donohoe D; Knape C; Lansky A; Attizzani GF; Fitzgerald P; Kandzari DE; Wijns W
    JACC Cardiovasc Interv; 2013 Oct; 6(10):1026-34. PubMed ID: 24055443
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Biodegradable-Polymer or Durable-Polymer Stents in Patients at High Bleeding Risk: A Randomized, Open-Label Clinical Trial.
    Valgimigli M; Wlodarczak A; Tölg R; Merkely B; Kelbæk H; Legutko J; Galli S; Godin M; Toth GG; Lhermusier T; Honton B; Dietrich PL; Stammen F; Ferdinande B; Silvain J; Capodanno D; Cayla G;
    Circulation; 2023 Sep; 148(13):989-999. PubMed ID: 37624364
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Determinants and Clinical Outcomes of Extended Dual Antiplatelet Therapy over 3 Years after Drug-Eluting Stent Implantation: A Retrospective Analysis.
    Lee OH; Kim BK; Hong SJ; Kim S; Ahn CM; Shin DH; Kim JS; Kang TS; Ko YG; Choi D; Hong MK; Jang Y
    Yonsei Med J; 2020 Jul; 61(7):597-605. PubMed ID: 32608203
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Validating Utility of Dual Antiplatelet Therapy Score in a Large Pooled Cohort From 3 Japanese Percutaneous Coronary Intervention Studies.
    Yoshikawa Y; Shiomi H; Watanabe H; Natsuaki M; Kondo H; Tamura T; Nakagawa Y; Morimoto T; Kimura T
    Circulation; 2018 Feb; 137(6):551-562. PubMed ID: 28982692
    [TBL] [Abstract][Full Text] [Related]  

  • 28. One-year clinical outcomes between biodegradable-polymer-coated biolimus-eluting stent and durable-polymer-coated drug-eluting stents in STEMI patients with multivessel coronary artery disease undergoing culprit-only or multivessel PCI.
    Kim YH; Her AY; Jeong MH; Kim BK; Lee SY; Hong SJ; Ahn CM; Kim JS; Ko YG; Choi D; Hong MK; Jang Y
    Atherosclerosis; 2019 May; 284():102-109. PubMed ID: 30877937
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Real polymer-free sirolimus- and probucol-eluting versus biodegradable polymer sirolimus-eluting stents for obstructive coronary artery disease: DKPLUS-Wave 1, a multicenter, randomized, prospective trial.
    Chen SL; Ye F; Zhang JJ; Zou JJ; Qian XS; Li F; Yang S; Ge Z; Shan SJ; Li XB; Xu T; Kan J; Lin L; Han YL
    Cardiovasc Ther; 2013 Aug; 31(4):193-200. PubMed ID: 22954234
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Biodegradable-Polymer Biolimus-Eluting Stents versus Durable-Polymer Everolimus-Eluting Stents at One-Year Follow-Up: A Registry-Based Cohort Study.
    Parsa E; Saroukhani S; Majlessi F; Poorhosseini H; Lofti-Tokaldany M; Jalali A; Salarifar M; Nematipour E; Alidoosti M; Aghajani H; Amirzadegan A; Kassaian SE
    Tex Heart Inst J; 2016 Apr; 43(2):126-30. PubMed ID: 27127426
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Rationale and design of the PARTHENOPE trial: A two-by-two factorial comparison of polymer-free vs biodegradable-polymer drug-eluting stents and personalized vs standard duration of dual antiplatelet therapy in all-comers undergoing PCI.
    Piccolo R; Calabrò P; Varricchio A; Baldi C; Napolitano G; De Simone C; Mauro C; Stabile E; Caiazzo G; Tesorio T; Boccalatte M; Tuccillo B; Bottiglieri G; Russolillo E; Di Lorenzo E; Carrara G; Cassese S; Leonardi S; Biscaglia S; Costa F; McFadden E; Heg D; Franzone A; Stefanini GG; Capodanno D; Esposito G
    Am Heart J; 2023 Nov; 265():153-160. PubMed ID: 37572785
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Safety of 3-Month Dual Antiplatelet Therapy After Implantation of Ultrathin Sirolimus-Eluting Stents With Biodegradable Polymer (Orsiro): Results From the SMART-CHOICE Trial.
    Yun KH; Lee SY; Cho BR; Jang WJ; Song YB; Oh JH; Chun WJ; Park YH; Im ES; Jeong JO; Oh SK; Cho DK; Lee JY; Koh YY; Bae JW; Choi JW; Lee WS; Yoon HJ; Lee SU; Cho JH; Choi WG; Rha SW; Lee JM; Park TK; Yang JH; Choi JH; Choi SH; Lee SH; Gwon HC; Hahn JY;
    J Am Heart Assoc; 2021 Jan; 10(1):e018366. PubMed ID: 33345567
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety of six-month dual antiplatelet therapy after second-generation drug-eluting stent implantation: OPTIMA-C Randomised Clinical Trial and OCT Substudy.
    Lee BK; Kim JS; Lee OH; Min PK; Yoon YW; Hong BK; Shin DH; Kang TS; Kim BO; Cho DK; Jeon DW; Woo SI; Choi S; Kim YH; Kang WC; Kim S; Kim BK; Hong MK; Jang Y; Kwon HM
    EuroIntervention; 2018 Mar; 13(16):1923-1930. PubMed ID: 29104179
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Twelve-month outcomes of patients unsuitable for prolonged DAPT presenting with an acute coronary syndrome and treated with polymer-free biolimus A9 drug-coated stents.
    Kinnaird T; Abdul F; Hailan A; Sheikh A; Hinton J; Yazji K; Elangovan S; Yousef A; Gallagher S; Choudhury A; Anderson R; O'Kane P; Smith D
    Catheter Cardiovasc Interv; 2018 Dec; 92(7):1220-1228. PubMed ID: 30244504
    [TBL] [Abstract][Full Text] [Related]  

  • 35. 6- versus 24-month dual antiplatelet therapy after implantation of drug-eluting stents in patients nonresistant to aspirin: the randomized, multicenter ITALIC trial.
    Gilard M; Barragan P; Noryani AAL; Noor HA; Majwal T; Hovasse T; Castellant P; Schneeberger M; Maillard L; Bressolette E; Wojcik J; Delarche N; Blanchard D; Jouve B; Ormezzano O; Paganelli F; Levy G; Sainsous J; Carrie D; Furber A; Berland J; Darremont O; Le Breton H; Lyuycx-Bore A; Gommeaux A; Cassat C; Kermarrec A; Cazaux P; Druelles P; Dauphin R; Armengaud J; Dupouy P; Champagnac D; Ohlmann P; Endresen K; Benamer H; Kiss RG; Ungi I; Boschat J; Morice MC
    J Am Coll Cardiol; 2015 Mar; 65(8):777-786. PubMed ID: 25461690
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Differential impact of abluminal groove-filled biodegradable-polymer sirolimus-eluting stent versus durable-polymer everolimus-eluting stent on and off dual antiplatelet therapy.
    Saito Y; Wijns W; Baumbach A; Xu B; Kelbaek H; Zheng M; Morel MA; Anderson R; Schächinger V; Lansky A;
    Catheter Cardiovasc Interv; 2022 Feb; 99(2):357-365. PubMed ID: 33502809
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Biodegradable Polymer Versus Polymer-Free Ultrathin Sirolimus-Eluting Stents: Analysis of the Stent Arm Registry From the HOST-IDEA Randomized Trial.
    Han JK; Yang S; Hwang D; Park SH; Kang J; Yang HM; Park KW; Kang HJ; Koo BK; Cho JM; Cho J; Bang DW; Lee JH; Lee HC; Kim KJ; Chun WJ; Seo WW; Park WJ; Park SM; Kim JW; Kim HS
    Circ Cardiovasc Interv; 2024 Jul; 17(7):e013585. PubMed ID: 38786579
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Safety and efficacy outcomes of 3rd generation DES in an all-comer population of patients undergoing PCI: 12-month and 24-month results of the e-Biomatrix French registry.
    Maupas E; Lipiecki J; Levy R; Faurie B; Karsenty B; Moulichon ME; Brunelle F; Maillard L; de Poli F; Lefèvre T
    Catheter Cardiovasc Interv; 2017 Nov; 90(6):890-897. PubMed ID: 28544186
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Stent Thrombosis in Drug-Eluting or Bare-Metal Stents in Patients Receiving Dual Antiplatelet Therapy.
    Kereiakes DJ; Yeh RW; Massaro JM; Driscoll-Shempp P; Cutlip DE; Steg PG; Gershlick AH; Darius H; Meredith IT; Ormiston J; Tanguay JF; Windecker S; Garratt KN; Kandzari DE; Lee DP; Simon DI; Iancu AC; Trebacz J; Mauri L;
    JACC Cardiovasc Interv; 2015 Oct; 8(12):1552-62. PubMed ID: 26493248
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Real-World Dual Antiplatelet Therapy Following Polymer-Free Sirolimus-Eluting Stent Implantations to Treat Coronary Artery Disease.
    Krackhardt F; Waliszewski M; Kočka V; Toušek P; Janek B; Hudec M; Lozano F; Roman KG; Del Blanco BG; Mauri J; Heang TM; Ahn TH; Jeong MH; Herberger D; Tomulic V; Levy G; Sebagh L; Rischner J; Pansieri M
    Cardiovasc Drugs Ther; 2020 Jun; 34(3):335-344. PubMed ID: 32212061
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.